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INTRODUCTION
Endometrial carcinoma is the most common
gynaecological malignant disease in devel-
oped countries.1,2 The incidence is increasing
worldwide, most likely related to the ageing
population. The majority of patients are post-
menopausal, with the peak age of occurrence
between 60 to 69 years.3 Following a meeting
of the International Federation of Gynecology
and Obstetrics (FIGO) in 1988, endometrial
carcinoma has since become a surgically
staged disease. (Table 1) Up to 83.2% of the
patients present at stages I and II of the
disease. The overall 5-year survival rate is
80%, and that for surgical stage Ia and Ib
disease is 91%.3
PRESENTATION AND
DIAGNOSIS
Many patients with endometrial carcinoma
present with irregular vaginal bleeding or
postmenopausal bleeding. Some may also
have coexisting risk factors, such as 
nulliparity, obesity, diabetes mellitus, 
hypertension, polycystic ovarian syndrome,
use of unopposed oestrogen, or familial
conditions like hereditary non-polyposis
colorectal cancer (HNPCC).  
An initial investigation by transvaginal
ultrasound (TVS) is a simple and non-invasive
test to exclude endometrial carcinoma. Using 5
mm as the cut-off to define abnormal endome-
trial thickening, 96% (95% confidence interval
[CI] 94%-98%) of women with endometrial
carcinoma, and 92% (95% CI 90%-93%) of
women with cancer polyp or atypical hyper-
plasia, had thickened endometrium.4 However,
a recent study showed that 34% of patients
with type II (see below, under “Prognostic
Factors”) endometrial carcinoma had thin or
indistinct endometrial thickness on ultrasound.5
Moreover, a meta-analysis on the use of
endometrial thickness in prediction of endome-
trial cancer showed that the detection rate was
63% (95% CI 58%-69%) with a 10% false-
positive rate, or 96% (95% CI 94%-98%) with
a 50% false-positive rate. This implies that 4%
of the patients with endometrial carcinoma
would still be missed even with a false-positive
rate as high as 50%.6
Endometrial aspiration is an effective
diagnostic method, which can be done with
simple devices like the Pipelle aspirator, and
the Novak, Vabra and Karman curettes. A
meta-analysis showed that endometrial biopsy
by Pipelle sampling achieved detection rates
of 99.6% and 91% for endometrial carcinoma
in postmenopausal and premenopausal
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women, respectively.7 Another systematic
quantitative review demonstrated that the
probability of endometrial cancer was 81.7%
(95% CI 59.7%-92.9%) for a positive test and
0.9% (95% CI 0.4%-2.4%) for a negative test
on endometrial biopsy.8 
Hysteroscopy with endometrial biopsy or
dilatation and curettage (D&C) is another
method used to diagnose endometrial carci-
noma. A meta-analysis involving 26,346
patients found that a positive finding in 
hysteroscopy (pooled likelihood ratio [LR] 60.9;
95% CI 51.2-72.5) increased the probability of
cancer to 71.8% (95% CI 67.0%-76.6%), while
a negative hysteroscopy result (pooled LR
0.15; 95% CI 0.13-0.18) reduced the proba-
bility of cancer to 0.6% (95% CI 0.5%-0.8%).9
The concern about peritoneal spillage of
tumour cells during hysteroscopy has been
raised. Studies have shown that although
there might be spread of tumour cells in the
abdominal cavity during the procedure, no
significant effect was found in the patients’
prognosis.10,11 Longer follow-up is certainly
needed to confirm these findings.  
In general, if a patient is suspected to
have endometrial carcinoma, endometrial
aspiration should be performed as first-line
investigation because it has higher sensitivity
than TVS. TVS can be used as a screening tool
when endometrial aspiration is not feasible,
for example in a patient who is never sexually
active or whose cervix is stenotic. A positive
ultrasound finding is an indication for
endometrial sampling for histological diag-
nosis. If endometrial aspiration or TVS are
inconclusive, or if there is a high clinical
suspicion despite negative result, diagnostic
hysteroscopy with endometrial biopsy or D&C
should be performed.
INVESTIGATION
Preoperative assessment includes investiga-
tions such as blood tests to assess the
patient’s general fitness for surgery, and
chest X-ray to exclude lung metastasis. Other
imaging techniques have also been advo-
cated for pre-operative staging. 
Computed tomography (CT) has a limited
value in detecting nodal involvement and
myometrial invasion,12,13 while magnetic reso-
nance imaging (MRI) is useful in assessing
myometrial invasion and has a sensitivity and
specificity of 50% to 90%.14-16 The sensitivity
and specificity of MRI in detecting cervical
invasion is 60% to 70% and 80% to 90%,
respectively; such knowledge enables the
surgeon to plan the extent of the operation.16,17
A recent trial comparing the effectiveness of
positron emission tomography (PET) with MRI
and CT showed that although PET had a
higher sensitivity in detecting extra-uterine
lesions, there was no difference in the speci-
ficity.18 PET was also insensitive in identifying
lymph nodes less than 1 cm in diameter,
limiting its routine use in pre-operative evalu-
ation of endometrial carcinoma. 
PROGNOSTIC FACTORS
There are several variables that influence the
patient’s outcomes. (Table 2) Among these,
the FIGO stage, differentiation grade (tumour
grade 1, 2 or 3 for each FIGO stage) and histo-
logical type of the disease correlate most
with the patient’s prognosis.3,19-21
The patient’s FIGO stage is the strongest
prognostic factor. The 5-year disease-free
survival has been demonstrated to be roughly
85% for stage I, 75% for stage II, 45% for
stage III, and 25% for stage IV.20-22 In the FIGO
staging system, the tumour is graded based
on the architectural features. Tumours with
≤5% solid growths are classified as grade 1,
Table 1. FIGO stage of endometrial carcinoma
Stage*
I Tumour confined to the corpus
IA Tumour limited to the endometrium
IB Invasion to less than half of the myometrium
IC Invasion equal to or more than half of the myometrium
II Tumour involving cervix
IIA Endocervical glandular involvement only
IIB Cervical stromal invasion
III Tumour limited to the pelvis
IIIA Tumour invades the serosa of the corpus uteri and/or adnexae and/or positive 
cytological findings
IIIB Vaginal metastases
IIIC Metastases to pelvic and/or para-aortic lymph nodes
IV Tumour invades local structures or metastases in distant sites
IVA Tumour invasion of bladder and/or bowel mucosa
IVB Distant metastases, including intra-abdominal metastasis and/or inguinal lymph nodes
* Each stage is subdivided in grade 1, 2 and 3 based on tumour grade.
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those with 6% to 50% as grade 2, and those
with >50% and those non-endometrioid carci-
nomas as grade 3. The presence of grade 3
nuclear features, including marked nuclear
pleomorphism, coarse chromatin and promi-
nent nucleoli, increases the tumour grade by
one.23 Increasing tumour grade worsens the
survival even within the same stage of the
disease.3 (Table 3)  
Myometrial invasion is also a compo-
nent of the staging system. It is recognized as
an independent factor of the patient’s
outcome. It has been shown that the 5-year
survival rates were 94% for stage I diseases
confined to the endometrium, and 91%, 84%
and 59% for those involving the inner third,
the middle third and the outer third of the
myometrium, respectively.24 A Gynecologic
Oncology Group (GOG) study showed that the
frequency of lymph node involvement
increased with the histological grade and the
depth of myometrial invasion.19 In that study,
the incidence of para-aortic and pelvic lymph
node metastasis was ≤5% for grade 1 or 2
tumours confined to the inner third of the
myometrium without extra-uterine spread.
However, the incidence of pelvic and aortic
node metastasis rose to 34% and 23%
respectively when the tumours were grade 3
diseases involving the outer third of the
myometrium.
The histological type of the tumour calls
for particular attention.  Endometrial carci-
noma has been classified into two types: type
I and type II.25 Type I tumours constitute 
about 80% of endometrial carcinoma.
Compared with type II tumours, type I
tumours tend to occur in premenopausal and
perimenopausal women. They are predomi-
nantly endometrioid carcinoma (EC), and are
usually preceded by endometrial hyperplasia.
They tend to be low-grade with minimal
myometrial invasion. Patients with this type
of tumours tend to have a favourable prog-
nosis. Uterine papillary serous (UPSC) and
clear cell (CC) carcinomas belong to type II
tumours and are more frequently associated
with high nuclear grade, deep myometrial
invasion, lympho-vascular permeation, lymph
node metastasis and abnormal p53 expres-
sion.26-28 Even when compared with patients
with grade 3 EC (G3EC), more patients with
UPSC and CC had stage III to IV diseases
(52% and 36% vs 29%; p<0.0001).29 
Lymphovascular invasion is associated
with poor survival, more recurrence and
lymph node metastasis.30 Tumour size less
than 2 cm had also been correlated with
better 5-year survival rate and less lymph
node metastasis.31 Other independent prog-
nostic factors include age,32 race,33 and
diabetes mellitus.34 On the other hand, the
presence of oestrogen and progesterone
receptors in endometrial cancer tissues is
associated with more favourable clinical
outcomes.35-36 Recent advances in molecular
science have drawn the focus to the genetic
and epigenetic changes in carcinogenesis.
Certain genes have been identified as poten-
tial prognosticators. For example, PTEN and
beta-catenin mutations are independent
predictors of earlier stage, better disease
grade and negative lymph node involve-
ment,37-39 while p53 and HER-2/neu mutations
are associated with advanced disease stage,
poor histological grade, lymph node meta-
stasis and poor clinical outcomes.39-44
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Table 2.  Independent prognostic factors in endometrial carcinoma
FIGO stage
Histological grade
Myometrial invasion
Histological type 
Vascular space invasion
Tumour size
Patients’ factors (eg, age, race, presence of diabetes mellitus)
Steroid receptor status
DNA ploidy and other biological markers (eg, microsatellite instability, PTEN, p53, Bcl-2, K-ras)
Table 3. Overall survival (%) at 5 years for different stages of
endometrial carcinoma for patients treated in 1999–2001 
Stage I Stage II Stage III Stage IV
Surgical grade 1 92.9 86.0 78.6 49.2
Surgical grade 2 89.9 80.0 67.3 26.5
Surgical grade 3 78.9 66.0 46.4 13.4
Adapted from reference 3.
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TREATMENTS
The management algorithm of patients with
stage I and occult stage II endometrial carci-
noma is summarized in Figure 1. In essence,
endometrial carcinoma should be treated 
by hysterectomy and bilateral salpingo-
oophorectomy if feasible, because patients
undergoing surgery with or without radiotherapy
have a 5-year survival rate of 80% to 90%, 
as compared with 40% to 50% only for those
receiving radiotherapy alone.45-46 In addition,
because there may be difficulty in determining
the stage of the disease pre-operatively and
intra-operatively, adjuvant radiotherapy may be
required after the final histological diagnosis is
made, in order to eradicate any occult lymph
node metastasis and to prevent vaginal vault
recurrence.  Different modes of treatment are
further elaborated below.
Surgery
The standard surgical treatment is total
abdominal hysterectomy and bilateral 
salpingo-oophorectomy (TAHBSO).  Peritoneal
washings, lymphadenectomy and biopsy of
any suspicious lesions are performed at the
same time for the purpose of staging.
Omentectomy is also performed in selected
cases such as in UPSC. For most patients,
these procedures serve both staging as well as
therapeutic purposes.
With the advent of laparoscopic surgery,
laparoscopic-assisted vaginal hysterectomy
(LAVH) and total laparoscopic hysterectomy
(TLH) have become more and more popular. A
randomized study involving 70 patients with
stage I to III diseases compared the outcomes
between LAVH and TAH. It was shown that
LAVH was better than TAH in terms of peri-
operative blood loss (229.2 ± 190.2 mL vs 594.2
± 629.9 mL, respectively; p=0.003), transfusion
rates (1/37 vs 11/33, respectively; p=0.005),
duration of infusion therapy (1.6 ± 0.76 days vs
2.8 ± 1.9 days, respectively; p=0.003), duration
to first bowel movement (2 ± 0.57 days vs 2.4 ±
0.75 days, respectively; p=0.02) and hospital
stay (8.6 ± 2.7 days vs 11.7 ± 3.8 days, respec-
tively; p<0.001). No difference was observed in
the yield of pelvic and para-aortic lymph nodes,
duration of surgery, incidence of postoperative
complications, and the overall and recurrence-
free survival rates.47
There has also been a randomized study
comparing LAVH with TLH, which showed
that the mean total operating time was
significantly shorter in the TLH than in the
LAVH group in experienced hands (184.0 ±
46.0 minutes vs 213.2 ± 39.4 minutes;
p=0.003). Further analysis showed that the
hysterectomy phase was shorter in the TLH
group only in overweight (68.1 ± 9.3 minutes
vs 77.9 ± 9.8 minutes for LAVH; p=0.005) and
obese patients (62.1 ± 9.9 minutes vs 87.7 ±
13.1 minutes for LAVH; p<0.0001), indicating
that TLH might benefit obese patients. There
was no significant difference in the esti-
mated blood loss, intra-operative and
post-operative complications, as well as 
the recurrence rate.48 Therefore, although
TAHBSO and staging are the gold standard of
treatment, LAVH and TLH should be consi-
dered as alternatives if expertise and
facilities are available.
For diseases involving the cervix apart
from occult stage II disease, radical hysterec-
tomy with parametrial removal has 
been advocated as it can result in better
survival rates when compared with simple
hysterectomy.49,50 Total laparoscopic radical
Figure 1. Management plan for patients with stage I and occult stage II
endometrial carcinoma
Laparotomy, hysterectomy, BSO, peritoneal cytology
With staging and 
lymphadenectomy 
Stage IAG1-2 and IBG1 (with / 
without lymphadenectomy
Stage IAG3 and IBG2 Stage IBG3
Stage IC any grade
Stage II (occult disease)
No further treatment
No further treatment 
or brachytherapy*
Without staging and 
lymphadenectomy
ERT or 
brachytherapy*
With staging and 
lymphadenectomy
No further treatment 
or brachytherapy or 
ERT*
Without staging and 
lymphadenectomy
ERT
With staging and 
lymphadenectomy
No further treatment 
or brachytherapy or 
ERT*
Without staging and 
lymphadenectomy
ERT
G = grade; ERT = external radiotherapy
* There is still no consensus on the standard treatment, and patients should be treated according to the protocol of individual centres
or in the context of a clinical trial.
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hysterectomy is a potential alternative to
open surgery, though experience is lacking.51,52
For more advanced or recurrent diseases,
cytoreduction should be considered in suitable
candidates. A study involving 33 stage IIIC and
nine stage IV patients reported that optimal
cytoreduction (residual tumour ≤2 cm) could
only be achieved in 72% of patients.53 The
median survival was 17.8 months and 6.7
months for patients with optimal and sub-
optimal cytoreduction, respectively (p=0.001).
Another study involving 65 stage IVB patients
showed that optimal cytoreduction (residual
tumour ≤1 cm) could be achieved in 55.4% of
patients.54 In a study from the same centre,
which involved 35 patients with recurrence of
endometrial carcinoma, reported that optimal
cytoreduction (no gross residual tumour) could
be achieved in 65.7% of patients. The median
survival time for those who had cytoreduction
was 28.0 months, as compared to 13.0 months
for those being treated non-surgically
(p<0.0001). Patients who underwent complete
salvage cytoreduction had a median post-
recurrence survival time of 39.0 months,
compared to 13.5 months for those with gross
residual diseases (p=0.0005).55 Pelvic exenter-
ation may also be considered in certain
patients with central recurrence, but this
surgical procedure can lead to both physical
and psychological morbidity.
Regarding the role of lymphadenectomy,
Kilgore et al found that patients who had
undergone multiple-site pelvic node sampling
had significantly better survival than patients
without node sampling (p=0.0002). This
survival benefit existed for both low-risk
(disease confined to the corpus) and high-risk
(disease in the cervix, adnexa, uterine serosa,
or washings) patients (low-risk, p=0.026; 
high-risk, p=0.0006).56 The COSA-NZ-UK
endometrial cancer study showed that the
recurrence rate was 45% for those node-
positive patients when compared with 14% for
those node-negative patients.57 The all-cause
survival and endometrial carcinoma survival
were also significantly better in those who had
complete negative lymphadenectomy (35/207
deaths; 22 from cancer) when compared with
those without complete lymphadenectomy
(226/774 deaths; 118 from cancer) (p<0.01).
However, a recent study from the Surveillance,
Epidemiology, and End Results (SEER) Program
showed that the survival benefit of extensive
lymphadenectomy only existed in the 
intermediate- and high-risk patients (stage IB,
grade 3; stage IC and II-IV, all grades). No
significant benefit of lymphadenectomy was
noted in the low-risk patients (stage IA, all
grades; stage IB, grades 1 and 2; p=0.23).58
Lymphadenectomy is an essential part
of staging which can help predict the 
prognosis of the patients. However,
lymphadenectomy can lead to significant
morbidity including lymphoedema (0.7%-
4.6%) and lymphocyst formation (1.3%-
1.9%); the SEER study showed that there 
was no significant survival benefit with
lymphadenectomy for patients with stage I
low-risk disease who have low incidence of
node metastasisas. Hence, some centres omit
lymphadenectomy for this group of patients
and perform it only for those who have
tumours with deep myometrial invasion as
shown by MRI preoperatively or sectioning of
the uterus intraoperatively, those found to
have grade 2 or 3 or non-endometrioid
tumours by endometrial biopsy preoperatively,
and those who have stage II diseases or
above.22,59
Radiotherapy
Radiotherapy is mainly used as an adjuvant
therapy. It has several modalities, including
vault brachytherapy, external pelvic irradia-
tion, extended-field irradiation, whole
abdominal irradiation, and intraperitoneal 32P.
Studies have shown that the 5-year survival
rate was more than 90% for patients with
stage I to II grade 1 to 2 diseases without
radiotherapy, suggesting that radiotherapy
might not be necessary for these patients.60-61
A prospective study conducted more
than 30 years ago compared the outcomes of
540 patients with stage I endometrial carci-
noma receiving either postoperative vaginal
brachytherapy alone, or brachytherapy with
additional pelvic irradiation. The latter group
had a significant reduction in vaginal and
pelvic recurrences (1.9 % vs 6.9%; p<0.01).
However, this group of patients had more
distant metastases (9.9% vs 5.4%).62 The
authors in this study concluded that only
patients with grade 3 tumours infiltrating more
than half of the myometrium could benefit
from external radiotherapy.
As for stage III and IV diseases, the use
of radiotherapy has been addressed by a
recent GOG study, which showed that the 3-
year recurrence-free survival rates were 29%
and 27%, and the survival rates were 31% and
35%, for type I and type II tumours respec-
tively, after external radiotherapy with or
without para-aortic boost.63 Certainly, the
treatment for this group of patients should 
be individualized and multi-modality treatment 
is needed.
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Evaluation of Surgery With and
Without Radiotherapy
Another multi-centre prospective randomized
trial, the PORTEC trial, compared surgery
(TAHBSO without lymphadenectomy) and
adjuvant radiotherapy (whole pelvic radio-
therapy) with surgery alone in 714 patients
with stage I endometrial carcinoma, including
those who had grade 1 disease with ≥50%
myometrial invasion, grade 2 disease with any
invasion, and grade 3 disease with <50% inva-
sion.64 Although there was significant
difference in the 5-year actuarial locoregional
recurrence rates between the radiotherapy
and control groups (4% vs 14%, p<0.001), no
difference was observed in the actuarial 5-
year overall survival rates (81% vs 85%;
p=0.31). There were 40 non-irradiated patients
who developed vault recurrence, but only four
of them died of it. In addition, radiotherapy
was associated with more complications (25%
vs 6%; p<0.0001).
The GOG-99 study evaluated the use of
radiotherapy after comprehensive surgery with
staging and lymphadenectomy in 392 patients
with stage IB to C, and stage II (occult)
diseases.65 The patients were further random-
ized into control and treatment (whole pelvic
radiotherapy) groups. The estimated 2-year
cumulative incidences of recurrence (CIR) were
12% and 3% for the control and treatment
groups, respectively (relative hazard [RH] 0.42;
p=0.007). The treatment difference was partic-
ularly evident among the following groups: (1)
those with grade 2 to 3 diseases, presence of
lymphovascular invasion, and outer third
myometrial invasion; (2) those aged ≥50 years
with any two risk factors listed above; or (3)
those aged at least 70 years with any risk
factor (2-year CIR 26% vs 6%; RH=0.42).
However, there was no difference in the esti-
mated 4-year survival between the control and
treatment groups (86% vs 92%, RH=0.86,
p=0.557).  
In addition, a recent Cochrane meta-
analysis showed that post-TAHBSO adjuvant
external beam radiotherapy reduced loco-
regional recurrence (relative risk [RR] 0.28,
95% CI 0.17-0.44, p<0.00001) in patients with
stage I disease, but such benefit did not confer
an advantage to the risk reduction of distant
recurrence and death from all causes or
endometrial cancer.66 A trend towards the
reduction in the risk of death from all causes or
endometrial cancer was however noted for
those with stage IC grade 3 disease. 
So far, adjuvant radiotherapy has not
been shown to be of survival benefit  for those
with stage I disease. The possible explanation
is that vault recurrence can readily be treated
by radiotherapy, with a complete remission
rate of up to 89%.67 Based on the above
evidence, it might be reasonable to omit radio-
therapy for low-risk patients with stage I
disease, especially those younger than 60
years of age. For those with stage I node-
negative intermediate- or high-risk disease after
comprehensive surgery with lymphadenectomy,
whether adjuvant radiotherapy is needed is
controversial. This is because although survival
outcomes were not compromised even if 
radiotherapy was not given,68-70 it can increase
the risk of local recurrence. Such practice is
subject to individual centres.
On the other hand, some studies have
suggested that external irradiation might be
replaced by vault brachytherapy for those at
low-risk or intermediate-risk without lymph
node metastasis after TAHBSO and selected
lymphadenectomy.57,71,72 Such modification
might potentially reduce complications
related to external radiotherapy. Whether
lymphadenectomy has a genuine positive
impact on the use of adjuvant radiotherapy is
still uncertain. The ASTEC (A Study in the
Treatment of Endometrial Cancer) trial, coordi-
nated by the Medical Research Council, UK, is
a randomized trial to determine the impact of
lymphadenectomy and adjuvant external
beam radiotherapy in the treatment of
endometrial carcinoma. It is still ongoing and
may perhaps provide some answers.
Chemotherapy
Chemotherapy is not the first-line treatment in
endometrial carcinoma. A number of trials
have been performed evaluating the use of
drugs such as cisplatin, carboplatin, paclitaxel,
doxorubicin, topotecan and so on, with or
without concomitant radiotherapy.  
A recent multi-centre phase II study
involving 42 patients with cytological or histo-
logical diagnosis of advanced or recurrent
endometrial carcinoma demonstrated an
overall response rate of 59.5% (95% CI 43.3-
74.3) when using carboplatin and liposomal
doxorubicin as first-line chemotherapy.73 The
major side effects were neutropenia, throm-
bocytopenia and anaemia. 
A recent meta-analysis of six trials
demonstrated that progression-free survival
was significantly improved when more inten-
sive chemotherapy was used in advanced or
recurrent diseases (HR=0.80, 95% CI 0.71-
0.90; p=0.004).74 However, the overall survival
was not improved (HR=0.90, 95% CI 0.80-
1.03; p=0.12).
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Another multi-centre phase II trial
investigated the effects of postoperative
radiotherapy and cisplatin and paclitaxel in
46 patients having grade 2 or 3 diseases with
either >50% myometrial invasion, cervical
stromal invasion or pelvic-confined extra-
uterine diseases.75 At 4-year follow-up, the
overall survival and disease-free survival
were 85% and 81%, and the pelvic, local and
distant recurrence rates were 2%, 2% and
19%, respectively.  From this study, it was
shown that the combination of adjuvant
chemotherapy and radiotherapy could provide
good local control but not distant metastasis.
Therefore, their efficacy should be further
explored by larger randomized controlled
trials.
Chemotherapy has also been used as an
adjunct to surgery in uterine papillary serous
carcinoma (USPC) and clear cell carcinoma of
corpus, with estimated 5-year overall survival
and progression-free survival rates of 79.7%
and 55.7%, respectively.76
Studies that have been carried out so far
have favoured the use of chemotherapy.
Further randomized trials are definitely
needed in order to define its role and design
its regimen in treating endometrial carcinoma.
Hormonal Therapy
The most commonly described hormonal
therapy is progestogen. Other hormonal
agents such as gonadotropin-releasing
hormone analogue (GnRHa), danazol and
tamoxifen have not demonstrated a satisfac-
tory effect.77-79 Although progesterone is
associated with minimal toxicity, its use in
adjuvant therapy has no effect on the overall
survival (OR 1.05; 95% CI 0.88-1.24), relapse of
disease (OR 0.81; 95% CI 0.65-1.01) and
cancer deaths (OR 0.88; 95% CI 0.71-1.1).80
For advanced or recurrent disease, the
response rate to progesterone is influenced
by the hormonal receptor status, being 5%
and 37% respectively, for the progesterone-
receptor negative and positive tumours
(p<0.001); and 7% and 26% respectively, for
the oestrogen-receptor negative and positive
tumours (p=0.005).81 Two phase II trials using
megestrol/medroxyprogesterone and tamo-
xifen have shown a response rate above 30%
in selected groups of patients with advanced
diseases.81-83 In addition, some centres have
also used medroxyprogesterone as a fertility-
sparing treatment for patients with clinically
stage I disease.84-87 Although successful preg-
nancies have been reported, the safety of
such treatment has to be confirmed by further
studies.
CONCLUSION
Significant advances have been made in the
management of endometrial carcinoma in the
last 2 decades.  Imaging tools such as CT, MRI
and PET have been more widely used pre-
operatively to assist in staging the disease
and planning the treatment.  Genetic and
epigenetic studies can potentially contribute
to the development of new prognostic
markers, the understanding of the carcinogen-
esis, and development of potential new
anti-cancer therapy.  With more experience,
the use of laparoscopic surgery can also
provide better treatment for patients in terms
of less peri-operative morbidity. Nevertheless,
this disease remains a challenge to oncolo-
gists. There are still a lot of unclear areas
waiting to be unravelled, including the need
for lymphadenectomy as well as radiotherapy,
which may be addressed by the ASTEC study.
Until further evidence arises, lymphadenec-
tomy should be performed as a staging
procedure, especially for those with deep
myometrial invasion or high-grade tumour as
shown by preoperative or intraoperative evau-
lation; adjuvant radiotherapy can be omitted
for those with stage I low-risk disease. There
is a potential role for chemotherapy and pro-
gesterone in advanced or recurrent diseases,
although further studies are needed to eluci-
date their roles.
About the Authors
Dr Tse is Resident Specialist, Dr Chan is Assistant
Professor, Dr Tam is Consultant, and Professor Ngan is
Professor at the Department of Obstetrics and
Gynaecology, Queen Mary Hospital, the University of Hong
Kong, Hong Kong SAR, China.
E-mail: tseky223@yahoo.com 
A list of references can be obtained upon request to the editorial office.
Continuing Medical Education
JPOG SEP/OCT 2007  •  219
Practice Points
• The incidence of endometrial
carcinoma is increasing worldwide.
• MRI is useful in defining the
myometrial invasion and cervical
extension. It has a potential role in
determining the necessity of
lymphadenectomy.
• Uterine papillary serous carcinoma
and clear cell carcinoma belong to
type II endometrial carcinoma and
are associated with poor outcomes.
• Laparoscopic hysterectomy is similar
to open hysterectomy in terms of
overall and recurrence-free interval.
• The role of lymphadenectomy and
radiotherapy has to be further
evaluated by randomized controlled
trials.
• Chemotherapy may be useful in
advanced or recurrent diseases.
• The role of progesterone is limited as
a palliative treatment, and the
response is influenced by the
hormonal receptor status.
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CME Article:
Current Concepts in the Management of Endometrial Carcinoma
Answer True or False to the questions below.
ANSWERS
12345678910
FFTTFFTFFT
1. Endometrial carcinoma is a clinically staged disease.
2. Spillage of fluid into the peritoneal cavity during hysteroscopy in patients with endometrial
carcinoma is associated with a worse prognosis.
3. Tumours with 6% to 50% solid growths are classified as grade 2.
4. The frequency of lymph node metastasis is increased with the depth of myometrial invasion.
5. Type II endometrial carcinoma is associated with endometrial hyperplasia.
6. The yield of lymph node obtained during laparoscopic operation is significantly less than
open operation.
7. Optimal cytoreduction can be achieved in 50% to 70% of patients with advanced or recurrent
diseases.
8. All studies so far demonstrate no survival benefit of lymphadenectomy for patients with low-
risk disease.
9. Adjuvant radiotherapy can decrease the risk of local and distant recurrence. 
10. Patients with advanced diseases may have a 20% to 30% response rate to
medroxyprogesterone.
True False
Learning is a lifelong business.
Read the Continuing Medical Education article in this issue, and test your understanding by answering the
following questions. 
Answers are shown at the bottom of this page. We hope you enjoy learning with JPOG.
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The Quiz
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